Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
131.86
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Beigene Ltd. (NASDAQ: BGNE) Highlighted for Surprising Price Action
April 06, 2023
Via
Investor Brand Network
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
BeiGene
Via
Business Wire
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
BeiGene Expands Presence in Latin America With Opening of Brazil Office
April 13, 2023
From
BeiGene
Via
Business Wire
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
March 30, 2023
From
BeiGene
Via
Business Wire
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
March 21, 2023
From
BeiGene
Via
Business Wire
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
February 24, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
February 24, 2023
From
BeiGene
Via
Business Wire
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
February 03, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
February 01, 2023
From
BeiGene
Via
Business Wire
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
From
BeiGene
Via
Business Wire
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
January 19, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
January 18, 2023
From
BeiGene
Via
Business Wire
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
January 17, 2023
From
BeiGene
Via
Business Wire
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
December 30, 2022
From
BeiGene
Via
Business Wire
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
December 13, 2022
From
BeiGene
Via
Business Wire
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
December 09, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
November 22, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
November 17, 2022
From
BeiGene
Via
Business Wire
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
November 15, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
November 10, 2022
From
BeiGene
Via
Business Wire
BeiGene Reports Third Quarter 2022 Financial Results
November 09, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
November 04, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
November 03, 2022
From
BeiGene
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
November 02, 2022
From
BeiGene
Via
Business Wire
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
October 26, 2022
From
BeiGene
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.